Profil
Andrew Kwon currently works at Whitehawk Therapeutics, Inc., as Senior Director-Business Development & Strategy from 2019.
Dr. Kwon also formerly worked at Radius Ventures LLC, as Associate.
Dr. Kwon received his undergraduate degree from Brown University, doctorate degree from the University of California, Los Angeles, and Masters Business Admin degree from Columbia Business School.
Aktive Positionen von Andrew Kwon
| Unternehmen | Position | Beginn |
|---|---|---|
| WHITEHAWK THERAPEUTICS, INC. | Corporate Officer/Principal | 01.01.2019 |
Ehemalige bekannte Positionen von Andrew Kwon
| Unternehmen | Position | Ende |
|---|---|---|
Radius Ventures LLC
Radius Ventures LLC Investment ManagersFinance Radius Ventures invests in companies located in the United States. The firm targets companies operating in the fields of healthcare and life sciences sectors. It provides financing for seed to early stage capital requirements with an investment size of USD 10 million. | Corporate Officer/Principal | - |
Ausbildung von Andrew Kwon
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
Brown University
Brown University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Los Angeles
University of California, Los Angeles Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Radius Ventures LLC
Radius Ventures LLC Investment ManagersFinance Radius Ventures invests in companies located in the United States. The firm targets companies operating in the fields of healthcare and life sciences sectors. It provides financing for seed to early stage capital requirements with an investment size of USD 10 million. | Finance |
Columbia Business School
Columbia Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aadi Bioscience, Inc.
Aadi Bioscience, Inc. BiotechnologyHealth Technology Develops mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases | Health Technology |
















